NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free DRMA Stock Alerts $0.38 +0.03 (+7.33%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$0.34▼$0.3950-Day Range$0.28▼$0.4452-Week Range$0.23▼$2.81Volume115,586 shsAverage Volume609,996 shsMarket Capitalization$2.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Dermata Therapeutics alerts: Email Address Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here About Dermata Therapeutics Stock (NASDAQ:DRMA)Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More DRMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRMA Stock News HeadlinesFebruary 11, 2024 | ca.finance.yahoo.comDermata Therapeutics, Inc. (DRMAW)February 6, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowMay 13, 2024 | InvestorPlace (Ad)Millionaire investor and Republican donor makes surprising election predictionFind out who Louis believes is going to win the election... And why that will launch a second boom in AI stocksFebruary 4, 2024 | morningstar.comDermata Therapeutics Inc DRMAFebruary 1, 2024 | finance.yahoo.comDermata to Present at the Emerging Growth Conference on February 7, 2024January 7, 2024 | msn.comDermata stock soars on patent issuance, partnership talksJanuary 5, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.comWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?May 13, 2024 | InvestorPlace (Ad)Millionaire investor and Republican donor makes surprising election predictionFind out who Louis believes is going to win the election... And why that will launch a second boom in AI stocksJanuary 5, 2024 | investorplace.comWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?January 4, 2024 | marketwatch.comStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion PharmaceuticalsJanuary 4, 2024 | marketwatch.comDermata Therapeutics Shares Surge 120% on Patent Issued in JapanJanuary 4, 2024 | msn.comWhy Dermata Therapeutics Stock Took Off After-HoursJanuary 4, 2024 | finance.yahoo.comDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of HyperhidrosisDecember 21, 2023 | finanznachrichten.deDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 20, 2023 | benzinga.comDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and DatesDecember 20, 2023 | finance.yahoo.comDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 13, 2023 | thestreet.comDermata Therapeutics Inc.November 16, 2023 | finance.yahoo.comDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesNovember 16, 2023 | finance.yahoo.comDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 ProtocolsNovember 10, 2023 | msn.comDermata Therapeutics GAAP EPS of -$0.54November 9, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne TrialAugust 31, 2023 | finance.yahoo.comDermata to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsJune 27, 2023 | finance.yahoo.comDermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe AcneJune 13, 2023 | finance.yahoo.comDermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETSee More Headlines Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRMA CUSIPN/A CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.95% Return on Assets-93.59% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.22Miscellaneous Outstanding Shares6,660,000Free Float6,035,000Market Cap$2.39 million OptionableNot Optionable Beta0.89 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Gerald T. Proehl (Age 65)Founder, President, CEO & Chairman Comp: $392kMr. David F. Hale (Age 75)Co-Founder & Lead Independent Director Comp: $73kMs. Kyri K. Van Hoose CPA (Age 46)M.B.A., Senior VP & CFO Comp: $415.8kDr. Christopher J. Nardo M.P.H. (Age 59)Ph.D., Senior VP & Chief Development Officer Comp: $443.52kMr. Sean ProehlSenior Director of Legal & Business DevelopmentDr. Maria Bedoya Toro Munera M.B.A. (Age 73)Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Comp: $27.04kMore ExecutivesKey CompetitorsSalarius PharmaceuticalsNASDAQ:SLRXCNS PharmaceuticalsNASDAQ:CNSPCohBarNASDAQ:CWBR60 Degrees PharmaceuticalsNASDAQ:SXTPSonoma PharmaceuticalsNASDAQ:SNOAView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 218,000 shares on 2/13/2024Ownership: 6.158%View All Institutional Transactions DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed in 2024? Dermata Therapeutics' stock was trading at $0.61 at the beginning of the year. Since then, DRMA shares have decreased by 41.0% and is now trading at $0.36. View the best growth stocks for 2024 here. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) announced its earnings results on Thursday, March, 21st. The company reported ($0.21) earnings per share for the quarter. When did Dermata Therapeutics' stock split? Shares of Dermata Therapeutics reverse split on the morning of Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $18 million in an IPO on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share. How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRMA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
